Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials

  title={Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials},
  author={Andrew D. Siderowf and Dag Aarsland and Brit Mollenhauer and Jennifer G Goldman and Bernard M. Ravina},
  journal={Movement Disorders},
Biomarkers have the potential to improve diagnosis and prognosis, and guide clinical treatment decisions. In research, biomarkers can be used for patient selection and as outcome measures in clinical trials. A range of biochemical and imaging biomarkers are relevant to patients with Lewy body disorders, including PD, PD dementia, and dementia with Lewy bodies. Dopaminergic imaging is used for differential diagnosis of parkinsonian disorders versus tremor disorders without dopamingeric deficits… Expand
Lewy Body Dementias: A Coin with Two Sides?
An overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD is provided, with a special focus on α-synuclein markers. Expand
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials
There are opportunities to improve the landscape of LBD clinical trials by harmonizing clinical assessments and biomarkers across cohorts and research studies, developing and validating outcome measures in LBD, engaging the patient community to assess research needs and priorities, and incorporating biomarker and genotype profiling in study design. Expand
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
This review covers molecules that might act as the biomarkers of Parkinson's disease and suggests that microRNA-based analysis may bring considerable progress, especially if it is combined with α-syn data. Expand
Early stages of Parkinson’s disease: aspects of the diagnosis and therapy
  • A. A. Pilipovich
  • 2019
Parkinson’s disease (PD) is the second most common neurodegenerative disease that is characterized by steady progression and results into persistent disability. It has been known that more than 10Expand
Cognitive Impairment and Dementia in Parkinson Disease.
To date, the field lacks curative or disease-modifying treatments for PD cognitive impairment and has few effective, robust symptomatic therapies for PDD or PD-MCI. Expand
Cognitive profile as a predictor of the long-term outcome after deep brain stimulation in Parkinson's disease
Cognitive profiles may stratify the pre-operative risk and predict long-term outcomes of deep brain stimulation in patients with Parkinson's disease. Expand
Living with Lewy body dementia. Treatment, survival & quality of life.
The importance of pharmacological and non-pharmacological management in LBD, particularly in view of the poor prognosis compared to the general population, is emphasised, addressing physical, social and psychological needs. Expand
Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
CSF α-syn RT-QuIC is a robust biomarker for prodromal DLB and indicates that MCI-LB patients against cognitively unimpaired controls with mild cognitive impairment due to probable Lewy body disease are identified. Expand
DAT imaging and myocardial MIBG scintigraphy for Lewy body diseases: A clinical‐neuroimaging study
Clinical‐neuroimaging data of 450 LBD patients was analyzed to answer the question which marker is more useful for identifying the three major LBD subtypes: Parkinson's disease, dementia with Lewy bodies, and the autonomic‐sleep variant. Expand
HFBD: a biomarker knowledge database for heart failure heterogeneity and personalized applications.
The HF biomarker knowledge database (HFBD), established by manually collecting the data and knowledge from literature in PubMed, provides a unique resource for the systematic understanding of HF heterogeneity and personalized diagnosis and treatment of HF in the era of precision medicine. Expand


Biomarkers for cognitive dysfunction in Parkinson's disease.
  • L. V. Kalia
  • Medicine
  • Parkinsonism & related disorders
  • 2018
Based on the neuropathological correlates of cognitive dysfunction in PD, significant efforts are underway to identify biomarkers that reflect the presence and degree of proteinopathy, neurodegeneration, including neuronal loss and axonal degeneration. Expand
Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease?
The ability to compare studies was limited by the heterogeneity of study populations, cognitive testing methods, and imaging protocols, and future work should adopt agreed scan protocols, be adequately powered, and use carefully phenotyped patients to fully maximize the contribution of MRI as a biomarker for PDD. Expand
Biomarkers for dementia and mild cognitive impairment in Parkinson's disease
This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients and concludes that no biomarker has as yet been validated. Expand
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
In PD, high neurofilament light chain protein, low Aβ1-42, and high heart fatty acid-binding protein at baseline were related to future PDD as analyzed by Cox proportional hazards regression models, providing new insights into the etiology of PDD. Expand
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Cerebrospinal fluid Abeta42 and total tau have a different behavior inDLB and PDD, being related to duration and severity of dementia in DLB alone, and Hyperphosphorylated tau is not significantly altered in these conditions. Expand
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
Cerebral neurofibrillary tangles burden, in addition to α-synuclein pathology and amyloid plaque pathology, are the strongest pathological predictors of a shorter interval between onset of motor and dementia symptoms and survival. Expand
Imaging amyloid deposition in Lewy body diseases
Global cortical amyloid burden is high in dementia with Lewy bodies (DLB) but low in Parkinson disease dementia, and data suggest that β-amyloid may contribute selectively to the cognitive impairment of DLB and may contribute to the timing of dementia relative to the motor signs of parkinsonism. Expand
Cognitive decline in Parkinson disease
New genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Expand
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
A role for tau copathology in the Lewy body diseases is supported, particularly in patients with DLB and in PD-impaired patients, even in those without elevated amyloid levels. Expand
Amyloid PET Imaging in Lewy body disorders.
  • P. Donaghy, Alan J. Thomas, J. O'Brien
  • Psychology, Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2015
Amyloid imaging is of limited use in the diagnosis of LB disorders but Aβ deposition may predict the future development of dementia in PD, and some results suggest a synergistic interaction between Aβ and α-synuclein. Expand